All studies
RecruitingPhase II and Phase III (Integrated)Interventional

PRODIGE 81-FFCD 2101-TRIPLET: Randomized, open-label, phase II-III study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy

This study focuses on adults with advanced hepatocellular carcinoma (the most common type of primary liver cancer) who have not yet received whole-body cancer treatment. The current standard first-line treatment uses two medicines given together: atezolizumab and bevacizumab. Atezolizumab is an immunotherapy that helps the body's immune system recognise and attack cancer cells, while bevacizumab blocks the blood supply tumours need to grow. In this trial, doctors want to find out if adding a third medicine, called ipilimumab, makes treatment more effective. Ipilimumab is another immunotherapy that works in a different way to boost the immune system. Participants are split into two groups: one receives standard care, and the other receives all three medicines. The main goals are to measure tumour shrinkage, track overall survival, and assess patient quality of life.

At a glance

Status
Recruiting
Phase
Phase II and Phase III (Integrated)
Sponsor
Fondation Franc.Cancerologie Digestive
Enrolment target
574
Start
27 Oct 2022

What is this study about?

Hepatocellular carcinoma is the most common form of primary liver cancer. When liver cancer cannot be removed with surgery, doctors treat it with systemic therapies. These are medicines that travel through the bloodstream to target cancer cells all across the body. Currently, the most effective standard first-line treatment is a combination of two drugs: atezolizumab and bevacizumab.

While this standard combination has helped many people, researchers want to see if they can improve results even further. The TRIPLET trial investigates whether adding a third drug, called ipilimumab, can attack the cancer more aggressively. Both atezolizumab and ipilimumab are immunotherapies, designed to switch on the body's natural defences against cancer, while bevacizumab works alongside them by cutting off the blood vessels feeding the tumour.

The study takes place in two connected stages. The first stage looks at how many patients see their tumours shrink or disappear during the first six months. The second stage looks at whether patients who receive all three drugs live longer overall than those receiving the standard two drugs. Throughout the study, doctors will also carefully monitor patient well-being and daily quality of life.

Key takeaways

  • Tests adding a third immunotherapy drug (ipilimumab) to standard liver cancer care.
  • Aimed at adults with advanced primary liver cancer starting their first systemic treatment.
  • Compares tumour shrinkage and overall survival between the two-drug and three-drug groups.
  • Medicines are given by regular intravenous drips in a hospital day unit.
  • Participation is entirely voluntary, with continuous health and safety monitoring.

Who may be eligible?

This trial is open to adults aged 18 and over who have been diagnosed with advanced hepatocellular carcinoma (primary liver cancer). It is designed specifically for people who are starting their first whole-body (systemic) treatment for liver cancer.

To take part, you must be in good enough general health to cope with regular hospital visits and intravenous treatments. Your medical team will check your liver function and general fitness to make sure it is safe for you to participate.

You may not be eligible if you have already had systemic drug treatments for this cancer, if you have certain active autoimmune conditions, or if your liver is too damaged by underlying disease. Your cancer specialist will go through detailed checks to see if this trial is a good match for your situation.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. You are aged 18 or older.
  2. You have a confirmed diagnosis of hepatocellular carcinoma (liver cancer).
  3. You have not yet received systemic (whole-body) drug therapy for this cancer.
  4. You are well enough to manage day-to-day activities and attend regular hospital visits.
  5. You are willing to receive regular intravenous infusions and undergo routine scans.
Answer every question to see your result.

What does participation involve?

If you join this study, you will receive your treatments as an infusion (a slow drip into a vein) in a hospital day clinic, typically every three weeks. A computer will randomly assign you to one of two groups: one group receives the standard two drugs, while the other group receives the three-drug combination. Neither you nor your doctor can choose your group.

You will attend regular hospital appointments for check-ups, safety blood tests, and scans (such as CT or MRI scans) every few weeks to monitor how the cancer is responding. You will also be asked to complete short questionnaires about how you are feeling day-to-day. Treatment usually continues for as long as your cancer is stable and any side effects remain manageable. Follow-up checks continue over several months or years to track your long-term health.

Potential risks and benefits

The potential benefit of joining this study is that you may receive a combination of medicines that shrinks your cancer more effectively and helps you live longer, though this cannot be promised. However, all cancer treatments carry a risk of side effects. Because immunotherapy stimulates your immune system, it can cause inflammation in healthy body parts like your bowels, skin, lungs, or liver. Adding a third medicine may increase the likelihood or severity of these reactions. Your hospital team will watch you very closely and can pause treatment or give other medicines to treat side effects. Taking part is completely voluntary, and you can leave the trial at any time without any change to your standard NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    France

Common questions

What is the main goal of this trial?

The study aims to find out if adding a third drug (ipilimumab) to standard liver cancer treatment shrinks tumours better and helps patients live longer.

How will I receive the trial medicines?

All the study drugs are given through an intravenous drip into a vein, usually during a day visit to the hospital clinic every three weeks.

Can I pick which treatment group I am in?

No. A computer randomly decides whether you receive the two-drug standard treatment or the three-drug combination. This ensures the study results are fair and reliable.

What side effects might I experience?

Common side effects of immunotherapy can include tiredness, skin rashes, diarrhoea, or liver inflammation. Your care team will monitor you closely and treat any issues quickly.

What happens if I decide to stop taking part?

You are free to leave the study at any time. If you decide to stop, your doctors will discuss other standard treatment options with you, and your regular NHS care will not be affected.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "PRODIGE 81-FFCD 2101-TRIPLET: Randomized, open-label, phase …" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.